The Complete® Self-Expanding Stent and Stent Delivery System Registry

Inclusion Criteria: * The lesion(s) is either de-novo or restenotic in nature, located in either the common iliac artery or the external iliac artery and is \>50% stenosed * Target vessel reference diameter ≥ 4.5 mm and ≤ 9.5 and can accommodate stent diameters of 6.0 - 10.0mm * Subject is either asymptomatic with a lesion stenosis ≥70% or symptomatic with a lesion stenosis ≥50% with an Ankle Brachial Index (ABI) \< 0.90 or Toe Brachial Index (TBI) \<0.80 or an abnormal Pulse Volume Recording (PVR); * Total lesion length is \< 110 mm; Exclusion Criteria: * Excessive Peripheral Vascular Disease (PVD), unresolved fresh thrombus or tortuosity or a target lesion/vessel that is heavily calcified ; * Tissue loss in the extremity: category 5 or 6 on the Rutherford scale; * Target lesion has a previous stent, or is within a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis; * Target lesion is within an aneurysm or associated with an aneurysm in the vessel segment proximal or distal to the target lesion; * Lesion requires treatment with a non-standard device associated with Percutaneous Transluminal Angioplasty (PTA) prior to stent placement; * Inadequate distal run-off; * Planned interventional procedure or vascular surgery to target vessel within 30 days pre- or post-index iliac procedure; * History of bleeding diatheses or coagulopathy or will refuse blood transfusions; * Platelet count \<50,000 cells/mm3 or \>700,000 cells/mm3, or White Blood Count (WBC) \<3,000 cells/mm3; * Creatinine \>2.0 mg/dl; * Participation in another investigational device or drug study and has not completed the primary endpoint(s) follow-up phase of that study at least 30 days prior to enrollment in this trial or the subject has previously been enrolled in this Registry;